BGM

BGM Group

--(--)

Market Open: --

--(--)

Post-Market: --

Key Stats

--DAY`S RANGE--

--52 WK RANGE--

Open

Prev.Close

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

Low

52 Week High

52 Week Low

About BGM

Bgm Group Ltd

Chinese pharmaceutical and chemical enterprises with traditional Chinese medicine as their main business

Industry

Pharmaceutical

Established Date

02/07/2019

Listing Date

01/12/2021

Exchange

NASDAQ Stock Exchange

Full-time Employees

323

Fiscal Year Ends

09-30

Website

www.bgmgroupltd.com

Security Type

Common stock

Office address

No. 152 Hongliang East 1st Street, No. 1703, Tianfu New District, Chengdu, 610200, People’s Republic of China

Business

Development, manufacturing and marketing of oxytetracycline products, licorice products, traditional Chinese medicine derivatives, heparin products, sausage casings and fertilizers

Introduction

Bomei Group Limited is a Cayman Islands exempted company incorporated on February 7, 2019. The company is a pharmaceutical and chemical company headquartered in China. The company currently has an API branch, Chengdu Qilianshan Biotechnology Co., Ltd., Jiuquan Qiming Biotechnology Co., Ltd., Jiuquan Ahan Biotechnology Co., Ltd., Tibet Shamen Trading Co., Ltd., Jiuquan Desert Licorice Biotechnology Co., Ltd., etc., It mainly produces solid preparations, antibiotic raw materials, traditional Chinese medicine extracts, crude heparin sodium, casings, pharmaceutical packaging materials, bio-organic fertilizers, antibacterial (antibacterial) products, disinfection products, etc. It is engaged in biological science research, biological product research and development, pharmaceutical technology research and development, self-produced products and domestic and foreign trade of various APIs, intermediates, chemical products, veterinary APIs and technologies. Among them, the raw material oxytetracycline and its preparation products occupy more than 35% of the domestic market share due to its advanced production technology, excellent and stable quality and sound marketing mechanism; the self-developed high-tech product compound licorice lozenges (Gan Dixin) is a national five-category new drug, a famous brand product in Gansu Province, and is exclusively produced in China. Its preparation method has won the national invention patent; the latest research and development product is a bacteriostatic ointment, With its unique advantages such as ancient prescriptions, exquisite selection of materials, reliable quality, and remarkable curative effects, it has been pursued by the majority of doctors and patients, and has driven out chronic diseases for many skin disease patients and brought good news. The trademarks of "Qilian Mountain" and "Gan Dixin" are well-known brands in China and famous trademarks in Gansu Province.

Company Financials

EPS

BGM has released its 2022 Q4 earnings. EPS was reported at 0.00, versus the expected 0.00, meeting expectations. The chart below visualizes how BGM has performed over recent quarters, highlighting trends in earnings surprises.